Imagine sitting in a hospital bed, pumped full of experimental chemicals, clinging to the hope of a cure. Now imagine a group of crypto bros and hedge fund managers placing bets on whether you’ll survive the next 90 days.
That isn’t a dystopian novel. It’s happening right now on platforms like Kalshi and Polymarket, where prediction markets allow people to gamble on the outcomes of clinical trials.
The immediate outcry from the public is about insider trading. Critics are terrified that biotech employees will use their insider knowledge to make a quick buck. And yes, that’s a valid fear. We’ve already seen companies like ChemoCentryx settle for $35 million over misleading data and overstated results. But focusing on insider trading misses the forest for the trees.
When you put a price tag on a clinical trial’s outcome, you don’t just incentivize insider trading—you incentivize rigging the actual science.
If a massive financial payout is tied to a drug failing, what stops bad actors from subtly manipulating the trial design? What stops a biotech executive from nudging an interim data release to swing the market in their favor? The financial incentive to manipulate human suffering isn’t a bug in these markets. It’s the core feature.
We all want miracle drugs to reach the market faster. We want the medical industry to be efficient. But you don’t speed up medical innovation by turning it into a casino. If these prediction markets distort the integrity of clinical trials, every single new drug approval becomes suspect.
You cannot commodify human suffering without eventually treating patients like poker chips.
The arrogance of this entire endeavor is breathtaking. We are building a system where a biotech company’s financial success is tied to a prediction market, which in turn is tied to how sick you get on their drug. The perverse incentives are so glaringly obvious that allowing them to exist should be considered an act of regulatory malpractice.
Market efficiency is a terrible excuse for turning a hospital ward into a trading floor.
This is ghastly, and it needs to be killed before it metastasizes. If we allow Wall Street to gamble on clinical trials, we aren’t just risking financial corruption—we are risking our lives. The next pill you swallow might be tainted by a trader’s bet. That’s not a risk anyone should be forced to take.
FAQ
Q: Isn't prediction market data actually useful for forecasting drug approvals?
A: No amount of forecasting efficiency is worth risking the integrity of clinical data. If the market can influence the outcome, the forecast is just self-fulfilling manipulation.
Q: How does this actually affect the average person?
A: If trial data is manipulated for financial gain, the drugs you rely on might be less effective or more dangerous than reported. Your health becomes collateral damage in a Wall Street bet.
Q: Shouldn't we just regulate insider trading instead of banning the markets?
A: Regulating insider trading doesn't fix the structural rot. The mere existence of a financial payout tied to a drug's failure creates a permanent incentive to rig the trial design itself.